<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472274</url>
  </required_header>
  <id_info>
    <org_study_id>DUTRENEO</org_study_id>
    <secondary_id>2017-002246-68</secondary_id>
    <nct_id>NCT03472274</nct_id>
  </id_info>
  <brief_title>Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)</brief_title>
  <acronym>DUTRENEO</acronym>
  <official_title>The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion CRIS de Investigación para Vencer el Cáncer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion CRIS de Investigación para Vencer el Cáncer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the treatment of localized/locally advanced urothelial cancer, there are several questions&#xD;
      that have not yet been resolved, such as the limited benefit of cisplatin-based chemotherapy&#xD;
      in the adjuvant or neoadjuvant context, the difficulty in establishing which groups actually&#xD;
      benefit from either perioperative treatment and what are the molecular markers that could&#xD;
      help us predict the response to this treatment to allow a better selection of patients. On&#xD;
      the other hand, not all patients are candidates for cisplatin-based chemotherapy and&#xD;
      carboplatin is not comparable in activity, so there is an urgent need to find other drugs&#xD;
      that may offer a therapeutic opportunity to these patients.&#xD;
&#xD;
      In the context of metastatic disease, immunotherapy has been able to modify the natural&#xD;
      history of this disease, administered as monotherapy, but the combination with double immune&#xD;
      checkpoint inhibitors is also being evaluated with promising results. Even this therapeutic&#xD;
      strategy is being advanced to the context of adjuvant and neoadjuvant treatment of urothelial&#xD;
      tumors. In this sense, on the one hand, the present study, as a research in the neoadjuvant&#xD;
      setting, constitutes the opportunity to define molecular phenotypes in bladder cancer since&#xD;
      the design of this study will allow both, to evaluate the efficacy of the drug when the tumor&#xD;
      is operable and to carry out an extensive analysis of biomarkers in the tumor tissue of these&#xD;
      patients with an in-vivo evaluation of immune-based therapy activity. On the other hand, it&#xD;
      allows to evaluate a strategy of double-immune checkpoint inhibitors that has already&#xD;
      demonstrated activity in metastatic disease and, taking into account, the modest benefit of&#xD;
      standard chemotherapy in the perioperative context: platinum-based neoadjuvant chemotherapy&#xD;
      in patients with muscle-invasive bladder cancer (MIBC) Modest increase in overall survival,&#xD;
      but only a subset of eligible patients are eligible to receive it. In addition, radical&#xD;
      cystectomy alone, in MIBC patients, presents a 5-year relapse rate of 10-50%.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>20 weeks</time_frame>
    <description>Evidence of residual disease based on pathological review of the surgical specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Objective Response Rate</measure>
    <time_frame>20 weeks</time_frame>
    <description>Number of complete response (CR) or partial response (PR) according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Number of disease recurrences according to RECIST v1.1 or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Number of deaths due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>20 weeks</time_frame>
    <description>Number of Adverse Events per patient using the National Cancer Institute Common Toxicity Criteria (CTC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers of response</measure>
    <time_frame>20 weeks</time_frame>
    <description>Candidate biomarkers of response in peripheral blood and tumor biopsy specimens that may prospectively identify subjects most likely to respond to treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarker expression</measure>
    <time_frame>20 weeks</time_frame>
    <description>Changes in biomarker expression in pre-treatment and post-treatment tumor samples of patients treated.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin-based neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:&#xD;
Regimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab plus Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1500 mg every 4 weeks x 3 cycles</description>
    <arm_group_label>Durvalumab plus Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Tremelimumab 75 mg every 4 weeks x 3 cycles</description>
    <arm_group_label>Durvalumab plus Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin-based neoadjuvant chemotherapy</intervention_name>
    <description>Regimen 1: 21-day treatment cycle x 3 cycles.&#xD;
Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.&#xD;
Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.&#xD;
Methotrexate 30mg/m2 intravenously on day 1&#xD;
Vinblastine 3mg/m2 intravenously on day 2&#xD;
Doxorubicin 30mg/m2 intravenously on day 2&#xD;
Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).&#xD;
Regimen 3: 21-day treatment cycle x 3 cycle&#xD;
Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8&#xD;
Paclitaxel 80 mg/m2 intravenously on day 1 and 8&#xD;
Cisplatin 70mg/m2 intravenously on day 1</description>
    <arm_group_label>Cisplatin-based neoadjuvant chemotherapy</arm_group_label>
    <other_name>Standard of care (SoC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects; age ≥ 18 years at the time of study entry.&#xD;
&#xD;
          2. Subjects must provide written informed consent prior to performance of any&#xD;
             protocol-related procedures, including screening evaluations and must be willing to&#xD;
             comply with treatment and follow up.&#xD;
&#xD;
          3. Subjects must have histologic documentation of transitional cell carcinoma of the&#xD;
             urothelium (including the urinary bladder, ureter, urethra and renal pelvis) of the&#xD;
             urinary tract (cystoscopy and biopsy or positive cytology).&#xD;
&#xD;
          4. Patients must have confirmed cT2-T4 N0-1 M0 (TNM classification).&#xD;
&#xD;
          5. Archival tumour samples for biomarker research in formalin-fixed and paraffin-embedded&#xD;
             blocks.&#xD;
&#xD;
          6. Body weight &gt;30kg&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          8. Life expectancy of at least 12 weeks&#xD;
&#xD;
          9. Adequate organ function as determined by:&#xD;
&#xD;
             a) Hematological (without growth factor or transfusion support within 28 days prior to&#xD;
             first dose of investigational product)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 GI/L).&#xD;
&#xD;
               -  Platelets ≥ 100,000/mm3 (≥ 100 GI/L)&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL (≥ 90 g/L)&#xD;
&#xD;
         10. Hepatic:&#xD;
&#xD;
               1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x upper&#xD;
                  limit of normal unless liver metastases are present, in which case it must be ≤5x&#xD;
                  ULN.&#xD;
&#xD;
               2. Total bilirubin ≤ 1.5 × the upper limit of normal. For subjects with Gilbert's&#xD;
                  disease ≤ 3 mg/dL (≤ 51.3 μmol/L).&#xD;
&#xD;
         11. Renal:&#xD;
&#xD;
             a) Calculated CrCl or 24-hour urine CrCl&gt;40 mL/min or Calculated creatinine clearance&#xD;
             CL&gt;40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for&#xD;
             determination of creatinine clearance&#xD;
&#xD;
         12. Fasting serum triglycerides ≤ 2.5 × upper limit of normal AND total cholesterol ≤ 300&#xD;
             mg/dL (≤ 7.75 mmol/L). Lipid-lowering medication is allowed.&#xD;
&#xD;
         13. HbA1c ≤ 8%.&#xD;
&#xD;
         14. Evidence of post-menopausal status or negative urinary or serum pregnancy test for&#xD;
             female pre-menopausal patients. Women will be considered post-menopausal if they have&#xD;
             been amenorrheic for 12 months without an alternative medical cause.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histology of pure adenocarcinoma, pure squamous cell carcinoma, or predominant small&#xD;
             cell carcinoma or sarcomatoid features in the tumor sample.&#xD;
&#xD;
          2. Evidence of any metastatic lesion outside the primary tumour site identified in the&#xD;
             radiological evaluation.&#xD;
&#xD;
          3. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab or tremelimumab. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids or local steroid injections (eg,&#xD;
                  intra-articular injection).&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                  prednisone or equivalent.&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (eg, CT scan&#xD;
                  premedication).&#xD;
&#xD;
          4. Previous therapy with PD-1, PD-L1 or CTLA-4 inhibitors, including durvalumab and&#xD;
             tremelimumab.&#xD;
&#xD;
          5. Any concurrent chemotherapy, immunotherapy (IMT), or biologic or hormonal therapy for&#xD;
             cancer treatment. Concurrent use of hormones for non-cancer-related conditions (eg,&#xD;
             insulin for diabetes and hormone replacement therapy) is acceptable.&#xD;
&#xD;
          6. History of severe allergic reactions (ie, Grade 4 allergy, anaphylactic reaction from&#xD;
             which the subject did not recover within 6 hours of institution of supportive care) to&#xD;
             any unknown allergens or any components of the study drug formulations.&#xD;
&#xD;
          7. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               -  Patients with vitiligo or alopecia&#xD;
&#xD;
               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               -  Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               -  Patients with celiac disease controlled by diet alone&#xD;
&#xD;
          8. Major surgery within 4 weeks of study randomization.&#xD;
&#xD;
          9. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.&#xD;
&#xD;
         10. Prior radiation therapy to &gt;25% of the bone marrow.&#xD;
&#xD;
         11. Current treatment on another clinical trial.&#xD;
&#xD;
         12. Diagnosis of any second malignancy within the last 3 years, except for adequately&#xD;
             treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.&#xD;
&#xD;
         13. Any of the following within the 12 months prior to starting study treatment:&#xD;
             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass&#xD;
             graft, congestive heart failure, cerebrovascular accident including transient ischemic&#xD;
             attack, or pulmonary embolus.&#xD;
&#xD;
         14. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms&#xD;
             calculated from 3 electrocardiograms (ECGs).&#xD;
&#xD;
         15. Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria&#xD;
             for Adverse Events (CTCAE) Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria&#xD;
&#xD;
               -  Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after&#xD;
                  consultation with the Study Physician.&#xD;
&#xD;
               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by&#xD;
                  treatment with durvalumab or tremelimumab may be included only after consultation&#xD;
                  with the Study Physician.&#xD;
&#xD;
         16. Hypertension that cannot be controlled by medications (&gt;150/100 mmHg despite optimal&#xD;
             medical therapy)&#xD;
&#xD;
         17. Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO&#xD;
             daily for deep vein thrombosis prophylaxis is allowed).&#xD;
&#xD;
         18. History of active primary immunodeficiency&#xD;
&#xD;
         19. Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and tuberculosis (TB) testing&#xD;
             in line with local practice), hepatitis B (known positive hepatitis B virus (HBV)&#xD;
             surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus&#xD;
             (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined&#xD;
             as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are&#xD;
             eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if&#xD;
             polymerase chain reaction is negative for HCV Ribonucleic acid (RNA).&#xD;
&#xD;
         20. Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B&#xD;
             or C or active hepatitis A.&#xD;
&#xD;
         21. Receipt of live, attenuated vaccine within 30 days prior to the first dose of&#xD;
             investigational products.&#xD;
&#xD;
         22. Pregnancy or breastfeeding. All female patients with reproductive potential must have&#xD;
             a negative pregnancy test (serum or urine) prior to randomization.&#xD;
&#xD;
         23. Other severe acute or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that would impart, in the judgment of the investigator, excess risk&#xD;
             associated with study participation or study drug administration, or which, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into this&#xD;
             study.&#xD;
&#xD;
         24. Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring AEs or compromise the ability of the patient to give written&#xD;
             informed consent&#xD;
&#xD;
         25. History of leptomeningeal carcinomatosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Grande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Moreno</last_name>
    <phone>+34918166804</phone>
    <email>ana.moreno@apices.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Font</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Mellado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Maroto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J García del Muro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Castellano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Puente</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Alonso-Gordoa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Álvaro Pinto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Álvaro Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Grande</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Durán</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel A Climent</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

